Form 10-Q BRAINSTORM CELL THERAPEU For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 1c
November 17, 2015 7:18 AM ESTBrainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.14), $0.01 better than the analyst estimate of ($0.15).
Third Quarter 2015 and Recent Highlights
Completed enrollment in Phase II, randomized, double-blind, placebo-controlled multicenter clinical trial of NurOwn® in ALS.Successful... More